Renin/prorenin receptor, (P)RR, in end-organ damage: current issues in 2007

Tadashi Inagami, Tsutomu Nakagawa, Atsuhiro Ichihara, Fumiaki Suzuki, Hiroshi Itoh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We present a critical review on emerging concepts on the role of (pro)renin receptor, (P)RR, in diabetic and hypertensive nephropathy. Discovery of nonproteolytic activation of prorenin by the receptor led to nontoxic peptidic prorenin receptor blocker. The receptor blocker permitted long-term in vivo studies on the role of (P)RR in diabetic and hypertensive end-organ damage. Chronic infusion of receptor blocker prevented streptozotocin diabetic nephropathy and attenuated hypertensive cardiomyopathy and nephropathy. In support of these results, transgenic rats overexpressing the receptor nonselectively developed renal glomerulopathy with aging without elevating blood glucose or blood pressures. It indicated that the receptor overexpression alone is sufficient for end-organ damage, and diabetes mellitus and hypertension induce the end-organ damage by increasing (P)RR expression. We propose that (P)RR is a pivotal link between pathogenesis of diabetes mellitus and end-organ damage. (P)RR seems to activate this mechanism largely by activating receptor signals rather than by local angiotensin II. We realized that (P)RR blocker is a competitive inhibitor against prorenin, and its efficiency depends on ambient concentration of prorenin and renin. Optimization of the condition will be necessary to maximize the inhibitory and therapeutic effects.

Original languageEnglish
Pages (from-to)205-209
Number of pages5
JournalJournal of the American Society of Hypertension
Volume2
Issue number4
DOIs
Publication statusPublished - 2008 Jul

Fingerprint

Renin
Diabetic Nephropathies
Diabetes Mellitus
Transgenic Rats
Therapeutic Uses
Streptozocin
Cardiomyopathies
Angiotensin II
Blood Glucose
Blood Pressure
Hypertension
Kidney
prorenin receptor
Hypertensive Nephropathy

Keywords

  • hypertension
  • Receptor blocker
  • streptozotocin diabetes mellitus

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Renin/prorenin receptor, (P)RR, in end-organ damage : current issues in 2007. / Inagami, Tadashi; Nakagawa, Tsutomu; Ichihara, Atsuhiro; Suzuki, Fumiaki; Itoh, Hiroshi.

In: Journal of the American Society of Hypertension, Vol. 2, No. 4, 07.2008, p. 205-209.

Research output: Contribution to journalArticle

Inagami, Tadashi ; Nakagawa, Tsutomu ; Ichihara, Atsuhiro ; Suzuki, Fumiaki ; Itoh, Hiroshi. / Renin/prorenin receptor, (P)RR, in end-organ damage : current issues in 2007. In: Journal of the American Society of Hypertension. 2008 ; Vol. 2, No. 4. pp. 205-209.
@article{3715bfe5d6574aa39384b7f8fbb530c6,
title = "Renin/prorenin receptor, (P)RR, in end-organ damage: current issues in 2007",
abstract = "We present a critical review on emerging concepts on the role of (pro)renin receptor, (P)RR, in diabetic and hypertensive nephropathy. Discovery of nonproteolytic activation of prorenin by the receptor led to nontoxic peptidic prorenin receptor blocker. The receptor blocker permitted long-term in vivo studies on the role of (P)RR in diabetic and hypertensive end-organ damage. Chronic infusion of receptor blocker prevented streptozotocin diabetic nephropathy and attenuated hypertensive cardiomyopathy and nephropathy. In support of these results, transgenic rats overexpressing the receptor nonselectively developed renal glomerulopathy with aging without elevating blood glucose or blood pressures. It indicated that the receptor overexpression alone is sufficient for end-organ damage, and diabetes mellitus and hypertension induce the end-organ damage by increasing (P)RR expression. We propose that (P)RR is a pivotal link between pathogenesis of diabetes mellitus and end-organ damage. (P)RR seems to activate this mechanism largely by activating receptor signals rather than by local angiotensin II. We realized that (P)RR blocker is a competitive inhibitor against prorenin, and its efficiency depends on ambient concentration of prorenin and renin. Optimization of the condition will be necessary to maximize the inhibitory and therapeutic effects.",
keywords = "hypertension, Receptor blocker, streptozotocin diabetes mellitus",
author = "Tadashi Inagami and Tsutomu Nakagawa and Atsuhiro Ichihara and Fumiaki Suzuki and Hiroshi Itoh",
year = "2008",
month = "7",
doi = "10.1016/j.jash.2007.12.006",
language = "English",
volume = "2",
pages = "205--209",
journal = "Journal of the American Society of Hypertension",
issn = "1933-1711",
publisher = "Elsevier Ireland Ltd",
number = "4",

}

TY - JOUR

T1 - Renin/prorenin receptor, (P)RR, in end-organ damage

T2 - current issues in 2007

AU - Inagami, Tadashi

AU - Nakagawa, Tsutomu

AU - Ichihara, Atsuhiro

AU - Suzuki, Fumiaki

AU - Itoh, Hiroshi

PY - 2008/7

Y1 - 2008/7

N2 - We present a critical review on emerging concepts on the role of (pro)renin receptor, (P)RR, in diabetic and hypertensive nephropathy. Discovery of nonproteolytic activation of prorenin by the receptor led to nontoxic peptidic prorenin receptor blocker. The receptor blocker permitted long-term in vivo studies on the role of (P)RR in diabetic and hypertensive end-organ damage. Chronic infusion of receptor blocker prevented streptozotocin diabetic nephropathy and attenuated hypertensive cardiomyopathy and nephropathy. In support of these results, transgenic rats overexpressing the receptor nonselectively developed renal glomerulopathy with aging without elevating blood glucose or blood pressures. It indicated that the receptor overexpression alone is sufficient for end-organ damage, and diabetes mellitus and hypertension induce the end-organ damage by increasing (P)RR expression. We propose that (P)RR is a pivotal link between pathogenesis of diabetes mellitus and end-organ damage. (P)RR seems to activate this mechanism largely by activating receptor signals rather than by local angiotensin II. We realized that (P)RR blocker is a competitive inhibitor against prorenin, and its efficiency depends on ambient concentration of prorenin and renin. Optimization of the condition will be necessary to maximize the inhibitory and therapeutic effects.

AB - We present a critical review on emerging concepts on the role of (pro)renin receptor, (P)RR, in diabetic and hypertensive nephropathy. Discovery of nonproteolytic activation of prorenin by the receptor led to nontoxic peptidic prorenin receptor blocker. The receptor blocker permitted long-term in vivo studies on the role of (P)RR in diabetic and hypertensive end-organ damage. Chronic infusion of receptor blocker prevented streptozotocin diabetic nephropathy and attenuated hypertensive cardiomyopathy and nephropathy. In support of these results, transgenic rats overexpressing the receptor nonselectively developed renal glomerulopathy with aging without elevating blood glucose or blood pressures. It indicated that the receptor overexpression alone is sufficient for end-organ damage, and diabetes mellitus and hypertension induce the end-organ damage by increasing (P)RR expression. We propose that (P)RR is a pivotal link between pathogenesis of diabetes mellitus and end-organ damage. (P)RR seems to activate this mechanism largely by activating receptor signals rather than by local angiotensin II. We realized that (P)RR blocker is a competitive inhibitor against prorenin, and its efficiency depends on ambient concentration of prorenin and renin. Optimization of the condition will be necessary to maximize the inhibitory and therapeutic effects.

KW - hypertension

KW - Receptor blocker

KW - streptozotocin diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=47049102213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47049102213&partnerID=8YFLogxK

U2 - 10.1016/j.jash.2007.12.006

DO - 10.1016/j.jash.2007.12.006

M3 - Article

C2 - 20409904

AN - SCOPUS:47049102213

VL - 2

SP - 205

EP - 209

JO - Journal of the American Society of Hypertension

JF - Journal of the American Society of Hypertension

SN - 1933-1711

IS - 4

ER -